The GLP-1 market now offers both injectable and oral formulations. Each format has advocates who cherry-pick data to make their preferred option look superior. We're going to skip that and give you the honest comparison.
Oral GLP-1s: What Exists Right Now
As of July 2026, the primary oral GLP-1 option is oral semaglutide, available as the brand-name prescription Rybelsus (for type 2 diabetes) and the recently launched oral Wegovy formulation (for weight management). Compounded oral semaglutide — including sublingual drops, troches, and dissolving tablets — is also available through telehealth providers, though the bioavailability data on compounded oral formulations is significantly less robust.
The bioavailability gap
Here's the number that matters: oral semaglutide has approximately 1% bioavailability. That means roughly 99% of the semaglutide you swallow is destroyed by your digestive system before it reaches your bloodstream. The remaining 1% is what produces the clinical effect.
To compensate, oral doses are much higher than injectable doses. A 14 mg oral tablet delivers a blood level roughly equivalent to a 0.5 mg injection. This isn't a problem — the dosing is calibrated to account for bioavailability — but it means oral and injectable doses aren't directly comparable by milligram count.
Injectable GLP-1s: The Established Standard
Injectable semaglutide (Wegovy) and tirzepatide (Zepbound) have the deepest clinical evidence base. The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) collectively enrolled tens of thousands of patients and demonstrated weight loss ranging from 12% to 22% of body weight over 68–72 weeks.
The injectable format delivers medication directly to the bloodstream with high bioavailability, producing consistent blood levels and predictable dose-response relationships. Decades of insulin delivery have made subcutaneous injection a well-understood route of administration.
The Real Trade-offs
Efficacy
Injectable GLP-1s have stronger weight loss data at this point. Oral formulations produce meaningful results but haven't yet matched the highest injectable doses in head-to-head comparisons. This gap may narrow as oral dosing is optimized and new oral compounds enter the market.
Convenience
Oral medications are easier to take — no needles, no refrigeration requirements, no injection technique to learn. For patients with needle anxiety or who travel frequently, the convenience factor is substantial. However, oral semaglutide must be taken on an empty stomach with minimal water and followed by a 30-minute fasting period, which is its own kind of inconvenience.
Side effects
GI side effects (nausea, vomiting, diarrhea, constipation) occur with both formats because they're driven by the mechanism of action, not the delivery route. Some patients report that oral formulations cause more upper-GI symptoms (heartburn, stomach discomfort) due to local effects in the stomach.
Cost
Brand-name oral Wegovy is priced comparably to injectable Wegovy. Compounded oral semaglutide may be less expensive than compounded injectable — but the bioavailability question means you may need higher doses, which can offset the price difference.
These providers offer both injectable and oral options for informed patient choice:
Providers Worth Investigating
We evaluated these programs based on the criteria discussed in this article. Listings are paid partnerships — our analysis is independent.